{
  "id": 1500,
  "text": "This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: $8 0 \\%$ ).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: \n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在治疗宫颈癌的患者中，尤其是处于 FIGO 分期 IIB-IIIB 或 IB-IIA 且伴有病理确诊的盆腔淋巴结转移或者肿瘤直径大于等于 5 厘米而无腹主动脉旁淋巴结转移的患者，治疗后常见的不良事件主要是血液学方面的问题。在接受治疗的患者中，31% 报告了与治疗相关的不良事件，其中最常见的是血液学异常，约占 80%。这些不良事件主要出现在治疗开始后的 90 天内。重要的是，在这类治疗中没有出现与治疗相关的严重不良事件。",
  "query": "宫颈癌患者在 FIGO 分期为 IIB-IIIB 或 IB-IIA 且伴有病理证实的盆腔淋巴结转移以及/或者肿瘤直径大于等于 5 厘米（但无病理证实的腹主动脉旁淋巴结转移）的情况下，治疗后常见的不良事件有哪些？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 宫颈癌患者在 FIGO 分期为 IIB-IIIB 或 IB-IIA 且伴有病理证实的盆腔淋巴结转移以及/或者肿瘤直径大于等于 5 厘米（但无病理证实的腹主动脉旁淋巴结转移）的情况下，治疗后常见的不良事件有哪些？\n\n<reference text>: This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: $8 0 \\%$ ).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在治疗宫颈癌的患者中，尤其是处于 FIGO 分期 IIB-IIIB 或 IB-IIA 且伴有病理确诊的盆腔淋巴结转移或者肿瘤直径大于等于 5 厘米而无腹主动脉旁淋巴结转移的患者，治疗后常见的不良事件主要是血液学方面的问题。在接受治疗的患者中，31% 报告了与治疗相关的不良事件，其中最常见的是血液学异常，约占 80%。这些不良事件主要出现在治疗开始后的 90 天内。重要的是，在这类治疗中没有出现与治疗相关的严重不良事件。"
}